Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (4094)	12/11/1998 10:41:00 AM
From: DavidCG	Respond to of 43080

CRII News out: FDA approval earlier this week now European approval today Its the FIRST Personal laser medical device approved by the FDA to replace steel needles and lancets in order for diabetes patients to monitor themselves for blood glucose. And its nearly painless. This is a HUGE market folks. CRII trading around $3 a share/ CHMD who markets this unit trades at $12...both great stocks. Each unit sells for approx $2k... will be lowered to $1k soon with an even more compact model 100 MILLION Diabetics world wide. If only 500K or .5% buys the unit(Meaning 99.5% of the diabetic population doesn't need to buy it) We are looking at a $1 BILLION DOLLAR + market No competition. Huge Market. And the stock trades only at $15 mil market cap. See the potential? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Friday December 11, 8:02 am Eastern Time Company Press Release SOURCE: Cell Robotics International, Inc. Cell Robotics Receives CE Mark to Market the Lasette in Europe ISO-9001 Certification for Cell Robotics and European Certification (CE Mark) for the Lasette has been granted. ALBUQUERQUE, N.M., Dec. 11 /PRNewswire/ -- Cell Robotics International, Inc. (OTC Bulletin Board: CRII - news), a manufacturer and marketer of medical and scientific laser devices, today announced that it has received ISO 9001 and EN46001 certification by ISO qualifying agency, TUV Essen. The award of this certification insures that Cell Robotics' products meet quality standards that have been accepted by over 100 countries and thousands of organizations throughout the world. ISO 9001 standards span 20 quality components of management, engineering, manufacturing, marketing and customer service. EN46001certification is a European requirement for medical devices. Receiving the ISO Certification was the final step for obtaining the CE Mark for the Lasette™, laser skin perforator. In addition, the Lasette must be tested against the stringent European standards for safety. The testing was completed and the data submitted in September 1998. The CE Mark was granted in December. The CE Mark is required for medical products to be shipped to and marketed in a number of countries, including all of Europe, Brazil, Argentina, Australia, New Zealand, South Korea and some other smaller countries. Receiving the CE mark allows Cell Robotics to immediately sell to the listed countries. Ronald K. Lohrding, Ph.D., chairman and chief executive officer of Cell Robotics, commented, ''We were very pleased that the FDA cleared the Lasette for home use on December 7, 1998; now the CE Mark opens up the even larger markets of Europe and other important countries. Customer response to the FDA home-use clearance has been far beyond our expectations and has inundated the Chronimed customer 800 number.'' Dr. Lohrding continued, ''In addition, the response from the national media in regard to the FDA's approval of the Lasette for home use has been astounding.'' Diabetes is a chronic disease that has no cure and is a leading cause of death worldwide. According to the International Diabetes Institute, www.idi.org.au/golbal.htn by 2000 there will be the following numbers of people with diabetes by region: 16.9 million in North America, 23.7 million in Europe, 51.2 million in Asia and 12.6 million in Latin America. These statistics illustrate how important the CE Mark is to Cell Robotics' and Chronimed's Lasette marketing efforts. Lasette is marketed and distributed by Chronimed, Inc.,(Nasdaq: CHMD - news) a leading integrated healthcare company specializing in products for people with chronic health conditions, such as diabetes, AIDS and organ transplants. Lasette product information is available through Chronimed at (800) 866-1633 or via e-mail (Lasette@chronimed.com). In addition to the Lasette, Cell Robotics International, Inc. manufactures, markets, and distributes scientific and medical laser devices. These devices include the In Vitro Fertilization (IVF) Workstation, designed to improve human fertility, and the Cell Robotics Workstation, a research instrument that incorporates the LaserTweezers® and LaserScissors™ for manipulating and cutting cells and chromosomes. Additional information is available on the Cell Robotics Web Site at www.cellrobotics.com, by e-mail at crii@cellrobotics.com., or by telephone at (505) 343-1131. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Maybe Shadow will pay attention this time since TMAX ultimately did go from $6 1/2 yesterday to $7 1/8 today. Maybe he'll like THIS GRAPH better. -DavidCG